Diplomat Pharmacy (DPLO) Now Covered by Analysts at Deutsche Bank

Deutsche Bank began coverage on shares of Diplomat Pharmacy (NYSE:DPLO) in a report issued on Monday morning. The brokerage issued a buy rating and a $22.00 target price on the stock.

Other equities research analysts also recently issued research reports about the company. Zacks Investment Research upgraded Diplomat Pharmacy from a hold rating to a strong-buy rating and set a $24.00 price target on the stock in a research report on Tuesday, October 10th. Robert W. Baird downgraded Diplomat Pharmacy from an outperform rating to a neutral rating and decreased their price objective for the stock from $24.00 to $18.00 in a report on Thursday, November 16th. Mizuho lifted their price objective on Diplomat Pharmacy from $16.00 to $20.00 and gave the stock a neutral rating in a report on Tuesday, November 7th. BidaskClub upgraded Diplomat Pharmacy from a hold rating to a buy rating in a report on Tuesday, September 26th. Finally, Leerink Swann raised their target price on Diplomat Pharmacy from $16.00 to $20.00 and gave the stock a market perform rating in a research note on Tuesday, November 7th. Six equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $20.39.

Diplomat Pharmacy (DPLO) traded up $0.48 during trading on Monday, hitting $18.21. The stock had a trading volume of 949,900 shares, compared to its average volume of 812,209. Diplomat Pharmacy has a 52-week low of $12.25 and a 52-week high of $21.99. The company has a quick ratio of 0.82, a current ratio of 1.34 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $1,250.00, a price-to-earnings ratio of 23.03, a P/E/G ratio of 3.19 and a beta of 0.61.

Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings results on Monday, November 6th. The company reported $0.25 EPS for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The firm had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.16 billion. During the same period last year, the company earned $0.21 earnings per share. The business’s revenue for the quarter was down 4.8% on a year-over-year basis. research analysts forecast that Diplomat Pharmacy will post 0.85 earnings per share for the current year.

In other news, Director Jeffrey G. Park acquired 3,000 shares of the firm’s stock in a transaction that occurred on Monday, November 20th. The stock was bought at an average cost of $15.46 per share, for a total transaction of $46,380.00. Following the acquisition, the director now directly owns 7,640 shares in the company, valued at $118,114.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Atul Kavthekar acquired 2,000 shares of the firm’s stock in a transaction that occurred on Monday, November 20th. The stock was purchased at an average price of $15.00 per share, with a total value of $30,000.00. Following the completion of the acquisition, the chief financial officer now owns 2,000 shares in the company, valued at $30,000. The disclosure for this purchase can be found here. Over the last three months, insiders bought 15,000 shares of company stock worth $228,780. Insiders own 30.20% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. State of Alaska Department of Revenue raised its holdings in Diplomat Pharmacy by 80.0% in the 2nd quarter. State of Alaska Department of Revenue now owns 8,623 shares of the company’s stock worth $127,000 after acquiring an additional 3,833 shares during the last quarter. PNC Financial Services Group Inc. grew its position in shares of Diplomat Pharmacy by 46.7% during the 2nd quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock valued at $130,000 after acquiring an additional 2,794 shares during the period. SG Americas Securities LLC bought a new stake in shares of Diplomat Pharmacy during the 3rd quarter valued at $191,000. Municipal Employees Retirement System of Michigan grew its position in shares of Diplomat Pharmacy by 4.9% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 10,250 shares of the company’s stock valued at $152,000 after acquiring an additional 480 shares during the period. Finally, Piedmont Investment Advisors LLC bought a new stake in shares of Diplomat Pharmacy during the 3rd quarter valued at $216,000. Institutional investors own 72.48% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/05/diplomat-pharmacy-dplo-now-covered-by-analysts-at-deutsche-bank.html.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply